Innovations Forged in the COVID Crucible Will Reshape Medicine Steve Usdin, Washington Editor Biopharmaceutical Report III Issue22_March 2021 The fight against COVID-19 is far from finished, but...
COVID-19 Long-Hauler Treatments Could Employ Repurposed Trial Endpoints to Prove Aptitude Biopharmaceutical Report II Issue23_March 2021 COVID-19 long-hauler treatment trials will likely rely on established endpoints and trial...
New SARS-CoV-2 Variants Push Back COVID-19 Vaccine Long-Term Durability Questions Biopharmaceutical Report I Issue23_March 2021 Long-term COVID-19 vaccine durability has become less of an endgame since it has become...
Prepping for COVID-19's Next Wave: Is the Glass Half Full or Half Empty? Biopharmaceutical Report IV Issue22_November 2020 COVID-19 didn’t disappear with summer temperatures, it just shifted locations and...
Lessons From Bergamo: Halting the Complement Cascade May Stop COVID-19 in Its Tracks Biopharmaceutical Report III Issue22_November 2020 Treatments for COVID-19 may be focusing on at the wrong elements of the disease,...
Fate and Celyad's CAR Therapies Offer Potential to Amplify Efficacy With Multiple Doses Biopharmaceutical Report II Issue22_November 2020 Fate Therapeutics’ (NASDAQ:FATE) and Celyad’s (NASDAQ:CYAD) natural killer (NK) cell...
Aurinia's Voclosporin Has Nephrotoxicity Concerns That Could Minimize First-Line Potential Biopharmaceutical Report I Issue22_November 2020 Aurinia Pharmaceutical’s (NASDAQ:AUPH) voclosporin has potential long-term...
Melanoma Trials Using Antibiotic or Microbiome Therapy Pretreatment Better Than Direct Combination Biopharmaceutical Report IV Issue21_April 2020 Early-phase melanoma trials testing microbiome approaches that leverage a broad- spectrum...
Evofem's Amphora Requires 12-month Data to Convince Experts of Contraceptive Efficacy Biopharmaceutical Report III Issue21_April 2020 Evofem’s (NASDAQ:EVFM) contraceptive gel Amphora leaves experts needing detailed 12-month...
Haste Plus Speed: The Need to Ensure COVID-19 Vaccines Don't Make Infections Worse By Sandi Wong, Assistant Editor Biopharmaceutical Report II Issue21_April 2020 "THERE IS A HUGH DIFFERENCE BETWEEN THE POSSIBILITY THAT A...
